The c-myc proto-oncogene is involved in the control of cell cycle progression, proliferation, metabolism, and apoptosis (1) (2) (3) . c-Myc protein is a transcription factor that functions via heterodimerization with MAX, a related protein that, like cMyc, contains basic, helix-loop-helix and leucine zipper domains but lacks the transactivation domain present in the amino terminus of c-Myc (4, 5) . MYC⅐MAX complexes stimulate transcription of target genes containing the MYC⅐MAX binding site (E-box) or specific non-canonical elements in their regulatory regions (6) . The expression of c-Myc protein is tightly controlled during cell proliferation and differentiation, because it is rapidly induced at cell cycle entry and expressed throughout the cell cycle, whereas it is turned off in quiescent and/or terminally differentiated cells (2, 3) . c-myc is one of the most frequently altered genes in human cancer (1, (7) (8) (9) . Overexpression of c-myc in transgenic mice causes tumor formation (10) . All these results demonstrate the central role of c-Myc in cell growth, proliferation, and transformation (3, (7) (8) (9) . The precise function of c-Myc protein, and in particular the mechanisms to induce transformation by c-Myc in normal and neoplastic cells, are not well characterized. Although many c-Myc target genes have been identified, elucidation of the molecular mechanisms will require extensive identification and characterizations of the downstream pathways regulated by c-Myc (1, 3, 11) .
Heat shock protein 90 (HSP90) 1 is a molecular chaperone and has been demonstrated to be involved in the folding of signal transduction molecules such as protein kinases (Src, Raf1, cdk4) and steroid receptors (12, 13) . Binding of HSP90 to steroid hormone receptors facilitates the ligand binding and is the critical step for hormone signaling (13) . HSP90 can also bind to different proteins such as apaf-1, IKK complex, calcineurin, cystic fibrosis transmembrane conductance regulator, aryl hydrocarbon receptor, p185/erbB2, Bcr-Abl, nucleophosmin-anaplastic lymphoma kinase, Akt kinase, receptor interacting protein, transcription factors (mutant p53, HIF-1␣), Gcn2, histones, and HSJ1b (human homolog of Escherichia coli DnaJ) to preserve them in active status and prevent their destabilization (14 -29) . In yeast studies, HSP90 is not generally involved in the folding of polypeptide chains, but the activity of many proteins depends on its function (12) . HSP90 is also shown to enhance telomerase activity and activate endothelial nitric-oxide synthase (30 -32) . HSP90 acts as a negative regulator of heat shock response by binding to heat shock transcription factor 1 and retains heat shock transcription factor 1 in the inactive, non-trimeric state (33) . In Drosophila, Hsp90 can buffer out the activity of mutant proteins to suppress genetic variations caused by these mutant proteins and modulate the speed of molecular evolution (34) . All these evidences suggest that HSP90 is involved in many important aspects of cellular processes. Increased expression of HSP90 in different types of human tumors also suggests its possible role in facilitating transformation in different human cancers (breast, prostate, bladder, pancreas, endometrium, brain, etc.) (30, (35) (36) (37) (38) (39) (40) (41) .
In this paper, we demonstrate that HSP90A (Hsp86␣ for mouse/rat homolog) is directly activated by c-Myc using different cell lines in different physiological conditions and tissue types. There is an E-box site in the 5Ј promoter of HSP90A gene that binds c-Myc. Overexpression of HSP90A in Rat1a cells induces soft agar colony formation and tumor formation in nude mice tumorigenicity assays. Repression of endogenous HSP90A/Hsp86␣ expression by siRNA reduces the transformation activity of HeLa and RatMyc cells. These results demonstrate that HSP90A is a c-Myc direct target gene contributing to c-Myc-induced transformation.
EXPERIMENTAL PROCEDURES
Reagents, Cell Lines, and Plasmids-The lymphoblastoid cell lines, U937, EREB.TCMyc, Rat.MycER TM , and RatMyc cells were described previously (42) (43) (44) . The HeBOCMVHSP90A plasmid was constructed by PCR-mediated generation of a ϳ2.2-kb fragment of the full-length human HSP90A cDNA from the plasmid pBS-HSP90A obtained from Dr. K. Yokoyama (RIKEN, Tsukuba Institute). The primers used to generate this fragment are 5Ј-TGGCTGTGCCGCTAGCCCTGTGCG-GTC-3Ј and 5Ј-TAAGTCATCCCTCGCCGGCGATTAGTCTA-3Ј. This fragment was subcloned into the NheI-NotI sites of HeBOCMV vector to make the HeBOCMVHSP90A expression vector (43) , and it was verified by sequencing. RatHsp cell lines were generated by transfecting the HeBOCMVHSP90A plasmid into Rat1a cells, and the cells were selected under G418 (400 g/ml). The NIH3T3.Myc cell line, 293TMyci, and HeLaMyci cell lines were as described (45) . The pSUPERHspi and pSUPERHspiR plasmids were generated by inserting the oligos of 5Ј-GATCCCTTCATCAGATGCATTGGACATTCAAGAGATGTCCAATGC-ATCTGATGAATTTTTGGAAA-3Ј and 5Ј-GATCCCCCAAAGAGATCT-TTCTGAGGGTTCAAGAGACCCTCAGAAAGATCTCTTTGTTTTTGG-AAA-3Ј into the pSUPER plasmids provided by Dr. R. Agami (46) . HeLaHspi and RatMycHspi cell lines were generated by transfecting pSUPERHspiϩpSV2Neo or pSUPERHspiRϩpSV2Neo into HeLa or RatMyc cells and selection under G418 (250 g/ml). Atlas human cDNA microarray filter was purchased from Clontech (Palo Alto, CA).
Northern Blot Analysis-15 g of total RNA was used in each lane of the Northern blots. The human HSP90A probe was generated by digestion of the pBS-HSP90A plasmid. The rat Hsp86␣ probe was generated by RT-PCR using rat-specific Hsp86␣ primers 5Ј-CCTAGTAAACTG-GACTCG-3Ј and 5Ј-CTTGTCACCATCCTTCTT-3Ј. The PCR fragment was subcloned into a pGEM-T vector and verified by sequencing. c-myc exon 3 and exon 1 probes were obtained from the pMC41RC and pMC41ER plasmids, respectively (47) . The exon-3 genomic c-myc probe detects both endogenous and exogenous (pTCMyc plasmid) c-myc RNA species, whereas the exon-1 c-myc probe detects only the endogenous c-myc RNA, because exon-1 sequences are not present in the transfected pTCMyc plasmid. The human ␤-actin, vimentin, and GAPDH probes were described previously (43) . Data shown here are representative of two or more experiments from independent cell cultures.
Western Blot Analysis-60 g of cellular extracts (CB control, CBMyc.Max, CBMax; see 8 ) were loaded to a 8% SDS-PAGE gel and transferred to nitrocellulose filters. The filters were probed with a polyclonal anti-HSP90A antibody (C-8262; Santa Cruz Biotechnology), an anti-c-Myc antibody (SC-764; Santa Cruz Biotechnology), and a polyclonal anti-␤-actin antibody (C-11; Santa Cruz Biotechnology) as a control for protein loading. Signals were revealed using an Amersham Biosciences ECL chemiluminescence kit. Data shown here are representative of two or more experiments from independent cell cultures.
Cloning of the Human HSP90A Promoter Region and Generation of HSP90A Promoter-driven Reporter Constructs, Transient Transfection, and Luciferase Assays-The genomic region flanking the HSP90A gene promoter was cloned by PCR amplification of human genomic DNA to generate a genomic fragment according to the published sequence (48, 49) , which contains 1430 bp 5Ј upstream of the HSP90A transcription start site, and the sequence was verified by sequencing. HindIII and BamHI sites were created to facilitate cloning. To generate the reporter construct driven by HSP90A promoter, a ϳ1.4-kb fragment containing 1430 bp 5Ј upstream of transcription start site was subcloned into the HindIII-BglII sites of the pXP2 vector to generate the HSPLuc1430 construct (44) . The HSPLuc1430Mut construct was made by changing the sequence from CACGTG to CACCTG in the HSPLuc1430 construct by site-directed mutagenesis. This reporter construct (0.1 g) was cotransfected with pMT2T, pMT2TMyc, or its deletion mutants (1 pmol) into 293T cells using the calcium phosphate transfection method. The total amount of transfected DNA and pMT2T sequences were kept constant in each experiment. A plasmid expressing the bacterial ␤-galactosidase gene (0.2 g; pCMV␤gal) was also co-transfected in each experiment to serve as an internal control for transfection efficiency. Two days after transfection, these cells were harvested, and their luciferase activities were assayed and normalized with ␤-galactosidase activities for transfection efficiency (44) . Each transfection was performed in triplicate, and standard deviation bars were shown. Data shown here are representative of three or more experiments from independent transfections.
Chromatin Immunoprecipitation (ChIP) Assay-ChIP assay was performed following the procedure as described (45, 50, 51) with minor modifications. Briefly, CBMyc.Max, CB33 control, or EREB.TCMyc cells were cross-linked with 1% formaldehyde for 10 min and stopped by adding glycine to a final concentration of 0.125 M. Fixed cells were washed twice with TBS (20 mM Tris, pH 7.5, 150 mM NaCl) and harvested in 5 ml of SDS buffer (50 mM Tris, pH 8.0, 0.5% SDS, 100 mM NaCl, 5 mM EDTA, and protease inhibitors). Cells were pelleted by centrifugation and suspended in 2 ml of IP buffer (100 mM Tris, pH 8.6, 0.3% SDS, 1.7% Triton X-100, 5 mM EDTA). Cells were sonicated with a 1 ⁄4-inch diameter probe for 15 s twice using an MSE-Soniprep1500 Sonicator (setting 18). For each immunoprecipitation, 1 ml of lysate was precleared by adding 50 l of blocked protein A beads (50% protein A-Sepharose (Amersham Biosciences), 0.5 mg/ml bovine serum albumin, 0.2 mg/ml salmon sperm DNA) at 4°C for 1 h. Samples were spun, and the supernatants were incubated at 4°C for 3 h with no antibody or polyclonal antibody specific for either c-Rel (SC-71; Santa Cruz Biotechnology) or c-Myc (SC-764; Santa Cruz Biotechnology). Immune complexes were recovered by adding 50 l of blocked protein A beads and incubating overnight at 4°C. Beads were successively washed with Mixed Micelle buffer (20 mM Tris, pH 8.1, 150 mM NaCl, 5 mM EDTA, 5% (w/v) sucrose, 1% Triton X-100, 0.2% SDS), Buffer 500 (50 mM Hepes, pH 7.5, 0.1% (w/v) deoxycholic acid, 1% Triton X-100, 500 mM NaCl, 1 mM EDTA), LiCl detergent wash buffer (10 mM Tris, pH 8, 0.5% deoxycholic acid, 0.5% Nonidet P-40, 250 mM LiCl, 1 mM EDTA), and TE and then eluted with 1% SDS and 0.1 M NaHCO 3 . 20 l of 5 M NaCl was added to the elutes and incubated at 65°C for 4 h to reverse the cross-linking. After digestion with proteinase K, the solution was phenol/ chloroform extracted and ethanol precipitated. DNA fragments were resuspended in 50 l of water. 5 l of the resuspended DNA was used in a PCR reaction for 30 cycles. The PCR reaction generated a 280-or 212-bp product. The primers used to generate the 280-bp fragment are 5Ј-CCC-AGCGTGCGCAACAGCTA-3Ј and 5Ј-TCATAGCCAGGCCCTCGGAA-3Ј. The primers used to generate the 212-bp fragment are 5Ј-CCAAGTCCC-CGATTCCCAAG-3Ј and 5Ј-AAAGAATCCAGCCGCAAGCG-3Ј. Input is 2% of total input lysate. Data shown here are representative of two or more experiments from independent immunoprecipitations.
Soft Agar Colony Assay-The stable clones were plated at three different cell densities (5 ϫ 10 3 , 10 4 , 2 ϫ 10 4 ) using standard assay conditions as mentioned except that 15% fetal calf serum was used (43) . Data shown here are representative of two or more experiments from independent cell cultures.
Nude Mice Tumorigenicity Assay-Tumorigenicity assays were performed as described (52) . Briefly, two Rat1a control clones, one RatMyc clone, and two RatHsp clones (10 7 cells each) were suspended in 200 l of phosphate-buffered saline and injected subcutaneously into 6-weekold athymic nude mice (BALB/c-nu mice; National Laboratory Animal Breeding and Research Center). Animals were monitored at periodic intervals for the appearance of tumors up to 50 days following injection.
RESULTS

Activation of HSP90A by c-Myc in Lymphoblastoid and Fibroblast Cell Lines Independent of Cellular Proliferation-
To identify c-Myc target genes, we exploited a previously described B cell line (EREB.TCMyc) in which proliferation and c-Myc expression could be controlled independently (43, 44) . Because in these cells the Epstein-Barr virus EBNA-2 gene (which induces B cell immortalization) is expressed as a chimeric fusion with the hormone binding domain of the estrogen receptor, estrogen (E2) removal leads to growth arrest (G 0 /G 1 ) associated with complete down-regulation of endogenous c-myc expression (see Fig. 1A , ϩTC/ϪE2 lanes) (53) . Because these cells have been transfected with a tetracycline (TC)-repressed c-myc vector, exogenous c-myc expression can then be induced by TC withdrawal. Induction of c-myc is not sufficient to cause cell cycle entrance, and the cells remain quiescent and viable for several days (43) . Using cDNA probes generated from RNAs harvested from cells in quiescent status (ϩTC/ϪE2) or from cells overexpressing exogenous c-myc (ϪTC/ϪE2), we screened a cDNA microarray filter containing cDNA clones corresponding to 1176 genes (Atlas Human array; Clontech). Among numerous genes displaying differential expression in c-myc expressing cells, we focused on the gene HSP90A because HSP90 was involved in many different aspects of cellular processes (12, 13) and its levels also increased in different tumor types (see the Introduction). To validate the result obtained from the microarray filter, we analyzed HSP90A expression upon c-myc induction in the same cells by Northern blot analysis. The results showed that withdrawal of estrogen and tetracycline (causing induction of exogenous c-myc) causes a 3-fold increase in the expression of HSP90A RNA (Fig. 1A) . This result also indicates that c-Myc can induce HSP90A expression in the absence of cell proliferation.
To further characterize HSP90A as a potential c-Myc target gene, we used a human Epstein-Barr virus-immortalized B cells (CB33) engineered by transfection to express high levels of either c-Myc⅐MAX (CBMyc.Max) or MAX⅐MAX (CBMax) complexes, representing the two regulatory situations of high and low c-Myc function, respectively (42) . The phenotypes of these cells were characterized previously and shown to be consistent with their differential c-Myc levels, because CBMyc.Max cells display a short doubling time, have clonogenic properties in vitro, and cause tumors in vivo, whereas CBMax cells proliferate slowly and lack any transformation-related phenotype. Northern blot analysis of these cell lines showed that the expression of HSP90A RNA increased significantly (ϳ2.5-fold) in CBMyc.Max cells when compared with control lymphoblastoid cells (CB control) or CBMax cells (Fig. 1B) . To examine whether increased c-myc and HSP90A expression were associated with increased protein levels, cell extracts from CB33 control, CBMyc. Max, and CBMax cells were analyzed by Western blot analysis using an anti-HSP90A antibody (Fig. 1C) . The results showed that CB33Myc.Max cells have increased levels (ϳ3-fold) of HSP90A protein.
To further confirm this correlation in different cell types, the expression of HSP90A by Northern blot analysis was shown to decrease in U937 cells induced into differentiation by 12-Otetradecanoylphorbol-13-acetate, which correlates with the decline in the mRNA levels of c-myc (Fig. 2A) . The levels of mouse Hsp86␣ expression also increased (ϳ3-fold) in NIH3T3 cells overexpressing c-myc when compared with control NIH3T3 cells (Fig. 2B) (54) . This pre-existing protein can be specifically activated by 4-hydroxytamoxifen (TM), but not by estradiol, allowing for the selective activation of pre-existing c-MycER TM in Rat.MycER TM cells (55) . By treating the cells with 4-hydroxytamoxifen, which specifically activates MYCER TM , and by simultaneous treatment with the protein synthesis inhibitor cyclohexamide (CX) to inhibit new protein synthesis, we examined whether Hsp86␣ gene expression could be regulated upon activation of pre-existing c-Myc-ER TM in the absence of de novo protein synthesis. Fig. 4 showed that TM treatment led to a significant (ϳ6.5-fold) and rapid (detectable after 1 ⁄2 h) increase in Hsp86␣ mRNA levels (left panel). This induction cannot be abolished by co-treatment with CX (CXϩTM) (Fig. 4, middle panel) , indicating that induction of Hsp86␣ gene expression involves a mechanism that is independent of de novo protein synthesis. The rapid kinetics of c-Myc-induced up-regulation and its independence of new protein synthesis are consistent with a direct effect of c-Myc activation on Hsp86␣ gene expression.
Transcriptional Regulation of HSP90A by c-Myc Requires an E-box Site in the Proximal
Promoter Region-To ascertain whether c-Myc up-regulates HSP90A gene expression at the transcriptional level, we first investigated whether the HSP90A promoter region contained c-Myc binding sites. The genomic organization of the 5Ј flanking region of human HSP90A gene is schematically reported in Fig. 5A . This region includes ϳ1.5 kb of upstream sequence from the HSP90A transcription start site. An E-box site (CACGTG) is located in the proximal promoter. We analyzed whether the c-Myc/MAX binding site could mediate transcriptional activation of the HSP90A by c-Myc by studying whether c-Myc could activate the transcription of a reporter gene linked to HSP90A promoter sequences (48, 49) . To this end, we constructed a reporter vector (HSPLuc1430; see Fig. 5A ) containing segments of the 5Ј flanking region and part of the exon 1 of the HSP90A gene linked to the promoterless coding domain of the luciferase gene (Luc) (43) . HSPLuc1430 was then co-transfected with either the control pMT2T or the pMT2TMyc expression vector into 293T cells. Fig. 5B showed that c-Myc was able to activate the expression of the HSPLuc1430 construct at levels (ϳ2.5-fold) comparable with those observed for other c-Myc target genes in this type of assays. To determine whether the E-box site was responsible for c-Myc-mediated activation, its sequence was changed from CACGTG to CACCTG using sitedirected mutagenesis, and the resulting reporter construct (HSPLuc1430Mut) was tested for c-Myc responsiveness in transient co-transfection assay. The results (Fig. 5B) showed that this mutant construct could not be activated by c-Myc, thus indicating that the E-box in the promoter region of the HSP90A gene mediates transcriptional activation by c-Myc. To further characterize the mechanism involved in c-Myc-mediated transactivation of HSP90A, we tested the function of c-Myc mutants lacking the transactivation domain (pMT2TMyc(⌬7-91)) or heterodimerization domain (pMT2TMyc(⌬371-412)) (56) . These two mutants were unable to induce the expression of the HSPLuc1430 construct (Fig. 5C) , indicating that c-Myc-mediated activation of HSP90A transcription required both the transactivation and heterodimerization domains with MAX, as expected for physiological c-Myc function. To determine whether c-Myc binds to the E-box in vivo, a ChIP assay using CB33Myc.Max cells was performed (45, 50, 51) . Fig. 5D , a showed that c-Myc, but not c-Rel, binds to the E-box as demonstrated by the c-Myc immunoprecipitated chromatin containing the proximal promoter fragment amplifiable to generate a 280-bp fragment. Control experiment to amplify another HSP90A proximal promoter fragment (212 bp) that did not contain an E-box failed to generate an amplifiable fragment (Fig. 5D, b) . The 280-bp fragment was also amplifiable from the c-Myc immunoprecipitated EREB.TCMyc(ϩTC/ϩE2) chromatin, demonstrating the binding of endogenous c-Myc to the proximal promoter E-box site (Fig. 5D, c) . In addition, the 280-bp fragment was not amplifiable in c-Myc immunoprecipitated chromatin prepared from CB33 control cells (Fig. 5D, d) or quiescent EREB.TCMyc(ϩTC/ϪE2) cells (data not shown). Positive control using the c-Myc immunoprecipitated chromatin from CBMyc.Max cells to amplify the promoter of a known c-Myc target gene, TERT (telomerase reverse transcriptase), generated an amplifiable fragment (data not shown) (51) . Taken together, these results indicate that c-Myc can induce direct activation of the HSP90A transcription by binding to the E-box site within the HSP90A proximal promoter region.
Induction of Transformation in Rat1a
Cells by Overexpressing HSP90A-To explore the role of HSP90A induction in c-Mycinduced transformation, we tested whether overexpression of HSP90A could mimic c-Myc in causing the transformation of Rat1a fibroblasts. Toward this end, an HSP90A expression vector was stably transfected into Rat1a cells, and the transfected Rat1a clones (RatHsp) were tested for their ability to produce colony in soft agar, a trait of malignant transformation. Fig. 6A showed the increased expression (50 to 70%) of HSP90A protein in RatHsp clones. Fig. 6B showed that three different Rat1a clones constitutively overexpressing HSP90A (RatHsp), but not control clones (RatCMV), have acquired clonogenicity in soft agar assays. Injection of these RatHsp clones into nude mice also caused significant tumor formation compared with control RatCMV clones, demonstrating the in vivo tumorigenicity of HSP90A overexpressing RatHsp clones (Fig.  6C) . Similar results were also obtained when HSP90A was overexpressed in HeLa cells. These HeLaHsp clones had increased soft agar colony formation and increased tumor volume in nude mice assays (data not shown). These results indicated that increased expression of HSP90A contributes to c-Mycinduced transformation.
Repression of Endogenous HSP90A in HeLa Cells by siRNA Reduces Their Transformation Activity-To test whether decreased HSP90A levels could lead to reduced transformation activity, a siRNA approach to knock down the endogenous HSP90A expression in HeLa cells was performed. Western blot analysis showed the decrease in the endogenous HSP90A levels of two different HeLa clones (HeLaHspi) compared with the control HeLa clone (Fig. 7A) . Transformation activity was assayed by soft agar colony formation performed on these HeLaHspi clones versus the control HeLa clone. Fig. 7B showed the significant decrease (50 to 75%) in soft agar colony numbers in these HeLaHspi clones compared with the HeLa control clone. This result indicated that the levels of HSP90A have direct correlation with transformation activity in HeLa cells.
Repression of Endogenous Hsp86␣ in RatMyc Cells by siRNA Reduces Their Transformation Activity-To test whether
Hsp86␣ up-regulation induced by c-Myc is critical for c-Mycmediated transformation, a siRNA approach to knock down the endogenous expression of Hsp86␣ in RatMyc cells was performed. Western blot analysis showed the decrease in the endogenous Hsp86␣ levels of two different RatMyc clones (RatMycHspi) compared with the control RatMyc clone (Fig. 8A) . Transformation activity was assayed by soft agar colony formation performed on these RatMycHspi clones versus the control RatMyc clone. bers of genes that are direct as opposed to secondary targets for c-Myc transcriptional activation. HSP90 has been identified as a potential c-Myc target gene from different differential screening (57) (58) (59) (60) (61) . Using different assay systems to characterize cMyc target genes, several genes (e.g. pdgf␤r, nucleolin) have been identified as bona fide c-Myc target genes (11) . Identification of true c-Myc target genes will exclude genes regulated through indirect consequence of c-Myc action. It will also demonstrate the molecular mechanism of c-Myc mediated direct transcriptional regulation and avoid misconceptions regarding the true activities of c-Myc (11) .
Overexpression of HSP90A in Rat1a and HeLa cells induced or enhanced transformation activity (Fig. 6 and data not shown), respectively, demonstrating the oncogenic property of HSP90A when its expression is increased. Overexpression of HSP90A either caused significant tumor formation (Rat1a cells; see Fig. 6C ) or increased tumor volume (HeLa cells) in nude mice assays (data not shown). HSP90A activation may be a crucial component of the program by which constitutive c-myc expression contributes to cell transformation. In addition, a new potent anticancer drug specifically against HSP90, geldanamycin, has been shown to inhibit different types of human cancer cell lines (62, 63) . siRNA experiments to repress the endogenous HSP90A levels in HeLa cells decreased their transformation activity (Fig. 7) . siRNA experiments to repress the endogenous Hsp86␣ levels in RatMyc cells also inhibited their transformation activity induced by overexpression of cMyc (Fig. 8) . These results are consistent with the role of increased HSP90A levels contributing to the process of malignant transformation.
HSP90 has been involved in many different aspects of cellular processes (12, 13) . How these processes contribute to transformation is still unknown. For example, the folding of protein kinases (Src, Bcr-Abl, Raf1, cdk4) facilitated by HSP90 to remain in active complexes may help to mediate transformation through the enhancement of their activity (13, 16) . The function of steroid receptors is determined by the binding of HSP90 to facilitate ligand binding (13) , which are related to different human cancers with hormone implications (breast cancers, prostate cancers, etc.). The involvement of erbB2 and Akt kinase with HSP90 may intensify their downstream signaling pathways (26, 29) . HSP90 interacts with HIF-1␣ to maintain its conformation and facilitate DNA binding, leading to promotion of angiogenesis (19) . HSP90 also prevents the degradation of receptor interacting protein to facilitate tumor necrosis factor-mediated nuclear factor-B activation and prevent apoptosis (21) . All these molecules with HSP90 involvement may play contributing roles in the process of transformation and tumorigenesis. The involvement of HSP90 with many different signal transduction pathways also makes it an ideal molecular target for cancer therapeutics (62, 63) .
Finally, assembly of active telomerase in rabbit reticulocyte lysates and in prostate tumor cell extracts in vitro requires HSP90 and p23 (30, 32, 64, 65) . Increased expression of HSP90A increased telomerase activity in HeLa cells in vivo (data not shown). The molecular mechanism of HSP90 enhanced telomerase activity may be the stable association of HSP90 with active telomerase complex (32, 65) . In addition, discordant regulation of TERT and telomerase activity was observed in some immortal cells and in the process of prostate carcinoma progression, demonstrating the importance of posttranslational regulation of telomerase protein (30, 64, 66) . HSP90-mediated enhancement of telomerase activity may be one of the major mechanisms modulating telomerase activity. c-Myc was demonstrated to directly activate TERT transcription and increase telomerase activity (44, 67) . Simultaneous activation of TERT and HSP90A by c-Myc coordinately increases telomerase activity through the increase in TERT mRNA and the overall telomerase activity, respectively, demonstrating the critical role of c-Myc in the regulation of telomerase activity. Coordinated regulation of telomerase activity by c-Myc may be one of the major mechanisms of c-Myc-mediated tumorigenesis. Taken together, increased HSP90A expression is contributing to transformation because of its involvement in many different cellular processes, demonstrating its role in the molecular mechanism of c-Myc-mediated transformation and tumorigenesis. 
